Aiming to become the global leader in chip-scale photonic solutions by deploying Optical Interposer technology to enable the seamless integration of electronics and photonics for a broad range of vertical market applications

Free
Message: Enough of the financing concerns

If you compare the disruptive tech Poet has to a phase 3 pharma drug on the verge of being FDA approved, Mazan's share price evaluation is quite plausible.

We should see a share price increase as we get closer to the 400G transceiver successfîul qualification. IMHO

 

GLTA

Share
New Message
Please login to post a reply